Overview Dividends

(PRME) Prime Medicine, Common Stock - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US74168J1016

Gene Editing, Prime Editing, pegRNA, Cell Therapy

Description: PRME Prime Medicine, Common Stock October 27, 2025

Prime Medicine, Inc. (NASDAQ: PRME) is a U.S.-based biotech firm that focuses on delivering therapeutic gene edits using its proprietary Prime Editing platform, which combines a modified Cas protein, a reverse-transcriptase domain, and a pegRNA to rewrite DNA without creating double-stranded breaks. The company’s current collaboration with Cimeio Therapeutics targets “shielded-cell” and immunotherapy pairs for genetic disorders, acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS). Incorporated in 2019 and headquartered in Cambridge, Massachusetts, PRME operates within the GICS Biotechnology sub-industry.

Key quantitative signals as of the latest filings: (1) market capitalization of roughly $300 million, indicating a small-cap valuation that is highly sensitive to trial outcomes; (2) cash and short-term investments of about $120 million, providing an estimated runway of 12–18 months under current burn rates; and (3) the broader prime-editing market is projected to grow at a CAGR of 22 % through 2030, driven by increasing FDA approvals of gene-editing therapies and rising R&D spend in the biotech sector, which averaged $23 billion annually in 2023. These drivers suggest that PRME’s upside potential is closely tied to successful IND submissions and partnership milestones.

If you want a data-rich, model-based view of PRME’s valuation and risk profile, the ValueRay platform offers a free analytical dashboard that can help you dig deeper.

PRME Stock Overview

Market Cap in USD 775m
Sub-Industry Biotechnology
IPO / Inception 2022-10-20

PRME Stock Ratings

Growth Rating -33.7%
Fundamental 41.0%
Dividend Rating -
Return 12m vs S&P 500 -5.13%
Analyst Rating 4.17 of 5

PRME Dividends

Currently no dividends paid

PRME Growth Ratios

Growth Correlation 3m 74.6%
Growth Correlation 12m 39.4%
Growth Correlation 5y -89.9%
CAGR 5y -37.17%
CAGR/Max DD 3y (Calmar Ratio) -0.39
CAGR/Mean DD 3y (Pain Ratio) -0.59
Sharpe Ratio 12m -1.73
Alpha -32.31
Beta 2.668
Volatility 107.71%
Current Volume 2969.2k
Average Volume 20d 3794.1k
Stop Loss 4.2 (-7.9%)
Signal -0.77

Piotroski VR‑10 (Strict, 0-10) 0.5

Net Income (-199.3m TTM) > 0 and > 6% of Revenue (6% = 297.7k TTM)
FCFTA -0.38 (>2.0%) and ΔFCFTA 40.66pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 1757 % (prev 234.3%; Δ 1523 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.36 (>3.0%) and CFO -99.9m > Net Income -199.3m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 3.56 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (129.2m) change vs 12m ago 8.39% (target <= -2.0% for YES)
Gross Margin -37.86% (prev 86.77%; Δ -124.6pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 1.84% (prev 24.67%; Δ -22.82pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -30.25 (EBITDA TTM -199.2m / Interest Expense TTM -6.81m) >= 6 (WARN >= 3)

Altman Z'' -16.15

(A) 0.31 = (Total Current Assets 121.3m - Total Current Liabilities 34.1m) / Total Assets 279.0m
(B) -2.84 = Retained Earnings (Balance) -791.7m / Total Assets 279.0m
warn (B) unusual magnitude: -2.84 — check mapping/units
(C) -0.77 = EBIT TTM -206.1m / Avg Total Assets 269.4m
(D) -3.63 = Book Value of Equity -791.7m / Total Liabilities 218.1m
Total Rating: -16.15 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 40.95

1. Piotroski 0.50pt = -4.50
2. FCF Yield -13.43% = -5.0
3. FCF Margin data missing
4. Debt/Equity 1.97 = 0.82
5. Debt/Ebitda -0.33 = -2.50
7. RoE -156.2% = -2.50
8. Rev. Trend 17.43% = 1.31
9. EPS Trend 66.37% = 3.32

What is the price of PRME shares?

As of November 04, 2025, the stock is trading at USD 4.56 with a total of 2,969,204 shares traded.
Over the past week, the price has changed by -11.46%, over one month by -27.85%, over three months by +1.33% and over the past year by +15.15%.

Is Prime Medicine, Common Stock a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Prime Medicine, Common Stock (NASDAQ:PRME) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 40.95 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PRME is around 3.32 USD . This means that PRME is currently overvalued and has a potential downside of -27.19%.

Is PRME a buy, sell or hold?

Prime Medicine, Common Stock has received a consensus analysts rating of 4.17. Therefore, it is recommended to buy PRME.
  • Strong Buy: 6
  • Buy: 2
  • Hold: 4
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the PRME price?

Issuer Target Up/Down from current
Wallstreet Target Price 6.6 45.4%
Analysts Target Price 6.6 45.4%
ValueRay Target Price 3.9 -14.9%

PRME Fundamental Data Overview November 01, 2025

Market Cap USD = 775.5m (775.5m USD * 1.0 USD.USD)
P/S = 156.3177
P/B = 19.5381
Beta = 2.668
Revenue TTM = 4.96m USD
EBIT TTM = -206.1m USD
EBITDA TTM = -199.2m USD
Long Term Debt = 119.7m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 14.5m USD (from shortTermDebt, last quarter)
Debt = 119.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 65.9m USD (from netDebt column, last quarter)
Enterprise Value = 796.9m USD (775.5m + Debt 119.7m - CCE 98.3m)
Interest Coverage Ratio = -30.25 (Ebit TTM -206.1m / Interest Expense TTM -6.81m)
FCF Yield = -13.43% (FCF TTM -107.0m / Enterprise Value 796.9m)
FCF Margin = -2157 % (FCF TTM -107.0m / Revenue TTM 4.96m)
Net Margin = -4017 % (Net Income TTM -199.3m / Revenue TTM 4.96m)
Gross Margin = -37.86% ((Revenue TTM 4.96m - Cost of Revenue TTM 6.84m) / Revenue TTM)
Gross Margin QoQ = -67.17% (prev -16.92%)
Tobins Q-Ratio = 2.86 (Enterprise Value 796.9m / Total Assets 279.0m)
Interest Expense / Debt = 0.36% (Interest Expense 434.0k / Debt 119.7m)
Taxrate = -0.0% (0.0 / -52.6m)
NOPAT = -206.1m (EBIT -206.1m * (1 - -0.00%)) [loss with tax shield]
Current Ratio = 3.56 (Total Current Assets 121.3m / Total Current Liabilities 34.1m)
Debt / Equity = 1.97 (Debt 119.7m / totalStockholderEquity, last quarter 60.9m)
Debt / EBITDA = -0.33 (negative EBITDA) (Net Debt 65.9m / EBITDA -199.2m)
Debt / FCF = -0.62 (negative FCF - burning cash) (Net Debt 65.9m / FCF TTM -107.0m)
Total Stockholder Equity = 127.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -71.42% (Net Income -199.3m / Total Assets 279.0m)
RoE = -156.2% (Net Income TTM -199.3m / Total Stockholder Equity 127.6m)
RoCE = -83.32% (EBIT -206.1m / Capital Employed (Equity 127.6m + L.T.Debt 119.7m))
RoIC = -161.5% (out of range, set to none) (NOPAT -206.1m / Invested Capital 127.6m)
WACC = 13.78% (E(775.5m)/V(895.2m) * Re(15.85%) + D(119.7m)/V(895.2m) * Rd(0.36%) * (1-Tc(-0.0)))
Discount Rate = 15.85% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 15.18%
Fair Price DCF = unknown (Cash Flow -107.0m)
EPS Correlation: 66.37 | EPS CAGR: 61.63% | SUE: 3.78 | # QB: 1
Revenue Correlation: 17.43 | Revenue CAGR: 161.6% | SUE: -0.13 | # QB: 0

Additional Sources for PRME Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle